



# Supplementary Materials: Designing Stable *Bacillus anthracis* Antigens with a View to Recombinant Anthrax Vaccine Development


Ekaterina M. Ryabchevskaya, Dmitriy L. Granovskiy, Ekaterina A. Evtushenko, Peter A. Ivanov, Olga A. Kondakova, Nikolai A. Nikitin and Olga V. Karpova




**Figure S1.** Original images of the western blot membranes represented in Figure 3.




**Figure S2.** Original images of the gels represented in Figure 4.




**Figure S3.** Images of the negative control samples without primary antibodies for the fluorescence analysis represented in the Figure 5 (a–j), and negative control (k—fluorescence analysis, l—phase contrast) represented by SPs-rPA1+2 compositions treated with chimeric monoclonal PA-neutralising antibodies and secondary antibodies conjugated to CF<sup>TM</sup> 488A.



**Figure S4.** Images of the control samples for the fluorescence analysis represented in the Figure 6a–c.



**Figure S5.** Original images of the gels represented in Figure 6d–e.



**Figure S6.** Images of the negative control samples without primary antibodies for the fluorescence analysis represented in the Figure 8.